Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $34.7 million.

  • Madrigal Pharmaceuticals' Change in Accured Expenses rose 1118.41% to $187.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 342.24%. This contributed to the annual value of $34.7 million for FY2024, which is 2444.02% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Change in Accured Expenses of $34.7 million as of FY2024, which was up 2,444.02% from -$1.5 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Change in Accured Expenses ranged from a high of $36.4 million in FY2022 and a low of -$1.5 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is $23.2 million, with a median of $34.7 million in 2024.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Change in Accured Expenses plummeted by 104.07% in 2023, and later surged by 2,444.02% in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $21.6 million in 2020, then plummeted by 54.48% to $9.8 million in 2021, then surged by 270.58% to $36.4 million in 2022, then crashed by 104.07% to -$1.5 million in 2023, then skyrocketed by 2,444.02% to $34.7 million in 2024.